Table 1 Baseline of enrolled patients with AEH and early EC in PKUPH
Variables | Control group | CR group | P-value* |
|---|---|---|---|
|  | N = 20 | N = 173 |  |
Time to CR | 10.15 ± 7.55 | 6.28 ± 6.01 | 0.011 |
Age (year) | 33.60 ± 4.94 | 32.59 ± 5.02 | 0.222 |
BMI (kg/m2) | 30.03 ± 4.33 | 26.87 ± 4.97 | 0.003 |
SBP (mmHg) | 130.45 ± 17.31 | 123.05 ± 14.18 | 0.095 |
DBP (mmHg) | 84.50 ± 13.56 | 79.27 ± 9.44 | 0.064 |
PP (mmHg) | 45.95 ± 10.23 | 43.78 ± 9.95 | 0.322 |
FBG (mmol/L) | 5.60 ± 3.04 | 5.41 ± 3.08 | 0.700 |
Serum insulin (mmol/L) | 29.79 ± 21.58 | 17.00 ± 11.31 | 0.001 |
TG (mmol/L) | 1.52 ± 0.84 | 1.57 ± 0.95 | 0.815 |
HDL (mmol/L) | 1.12 ± 0.23 | 1.17 ± 0.33 | 0.599 |
Cholesterol (mmol/L) | 5.18 ± 0.81 | 4.62 ± 0.85 | 0.005 |
LDL (mmol/L) | 16.28 ± 57.13 | 2.92 ± 0.73 |  < 0.001 |
CA125 (IU/mL) | 16.70 ± 8.82 | 19.54 ± 16.95 | 0.655 |
ER range( %) | 0.73 ± 0.28 | 0.76 ± 0.21 | 0.970 |
PR range (%) | 0.82 ± 0.18 | 0.75 ± 0.28 | 0.923 |
p53 range (%) | 0.50 ± 0.48 | 0.30 ± 0.40 | 0.134 |
Ki-67 range (%) | 0.27 ± 0.19 | 0.20 ± 0.13 | 0.184 |
Menstruation regularity | Â | Â | 0.145 |
 Yes | 3 (15.00%) | 53 (30.64%) |  |
 No | 17 (85.00%) | 120 (69.36%) |  |
Gestation | Â | Â | 0.358 |
 No | 17 (85.00%) | 107 (61.85%) |  |
 Yes | 3 (15.00%) | 66 (38.15%) |  |
Parity | Â | Â | 0.034 |
 No | 19 (95.00%) | 143 (82.66%) |  |
 Yes | 1 (5.00%) | 30 (17.34%) |  |
PCOS | Â | Â | 0.307 |
 No | 11 (55.00%) | 115 (66.47%) |  |
 Yes | 9 (45.00%) | 58 (33.53%) |  |
Thyroid disease | Â | Â | 0.592 |
 No | 17 (85.00%) | 154 (89.02%) |  |
 Yes | 3 (15.00%) | 19 (10.98%) |  |
Family history | Â | Â | 0.835 |
 No | 18 (90.00%) | 153 (88.44%) |  |
 Yes | 2 (10.00%) | 20 (11.56%) |  |
Hypertension | Â | Â | 0.011 |
 No | 15 (75.00%) | 160 (92.49%) |  |
 Yes | 5 (25.00%) | 13 (7.51%) |  |
Diabetes | Â | Â | 0.870 |
 No | 16 (80.00%) | 141 (81.50%) |  |
 Yes | 4 (20.00%) | 32 (18.50%) |  |
Metformin use | Â | Â | 0.772 |
 No | 11 (55.00%) | 101 (58.38%) |  |
 Yes | 9 (45.00%) | 72 (41.62%) |  |
Medication use | Â | Â | 0.109 |
 Single | 11 (55.00%) | 125 (72.25%) |  |
 Combined | 9 (45.00%) | 48 (27.75%) |  |
Maintenance treatment | Â | Â | 0.030 |
 No | 8 (40.00%) | 33 (19.08%) |  |
 Yes | 12 (60.00%) | 140 (80.92%) |  |
Histological type | Â | Â | 0.010 |
 AEH | 5 (25.00%) | 96 (55.49%) |  |
 Early EC | 15 (75.00%) | 77 (44.51%) |  |
ER intensity | Â | Â | 0.014 |
  +  | 6 (30.00%) | 86 (58.11%) |  |
  +  +  | 2 (10.00%) | 21 (14.19%) |  |
  +  +  +  | 12 (60.00%) | 41 (27.70%) |  |
PR intensity | Â | Â | 0.005 |
 Negative | 0 (0.00%) | 5 (3.40%) |  |
  +  | 4 (20.00%) | 72 (48.98%) |  |
  +  +  | 2 (10.00%) | 26 (17.69%) |  |
  +  +  +  | 14 (70.00%) | 44 (29.93%) |  |
p53 | Â | Â | 0.408 |
 Negative | 4 (21.05%) | 37 (30.33%) |  |
 Positive | 15 (78.95%) | 85 (69.67%) |  |